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Abstract  
Background: The right ventricular apex (RVA) is the traditional lead site for chronic 
pacing but in some patients may cause impaired left ventricular (LV) systolic function 
over time.  Comparisons with non-apical (RVNA) pacing sites have generated 
inconsistent results and recent meta-analyses have demonstrated unclear benefit 
due to heterogeneity across studies. 
Methods and Results: A systematic search for randomized controlled trials that 
compared LVEF outcomes between RVNA and RVA pacing was performed up to 
October 2014. Twenty four studies (n=1,628 patients) met the inclusion criteria. To 
avoid between study heterogeneity two homogenous groups were created; group 
one where studies reported a difference (in favor of RVNA pacing) and group two 
where studies reported no difference between pacing sites. For group one weighted 
mean difference (WMD) between RVNA and RVA pacing in terms of LVEF at follow-
up was  5.40% (95% CI: 3.94 to 6.87), related in part to group one’s RVA arm 
demonstrating a significant reduction (mean loss -3.31%; 95% CI: -6.19 to -0.43) in 
LVEF between study baseline and end of follow-up. Neither of these finding were 
seen in group two. Weighted regression modeling demonstrated that inclusion of 
poor baseline LVEF (<40%) in combination with greater than 12 months follow-up 
was three times more common in group one compared to group two (weighted RR 
2.82; 95% CI 1.03 – 7.72; P=0.043).  
Conclusions: In patients requiring chronic right ventricular pacing where there is 
inclusion of impaired baseline LVEF (<40%), RVA pacing is associated with 
deterioration in LV function relative to RVNA pacing.   
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Introduction 
The right ventricular apex (RVA) has been the traditional site of choice for permanent 
pacing lead placement worldwide.1, 2 The technology has proven stable and safe over long 
periods of time. Accumulating experimental and clinical data suggest, however, that RVA 
pacing can potentially result in long-term deleterious effects on left ventricular (LV) systolic 
function in some patients, increasing the risk of heart failure and death.3-5 Concern about 
RVA pacing has driven an examination of non-apical sites and have included the right 
ventricular septum, outflow tract area and the His bundle.4, 6 Accurate septal lead placement 
has, until recently proven unreliable and so a general term, right ventricular non-apical 
pacing sites (RVNA) has been adopted to cover all sites deemed not to be apical. Septal 
pacing, being theoretically closer to the His-Purkinje system has been felt more likely to 
avoid LV dysfunction.4  In the late 1990s two small randomized controlled trials (n<35 
participants) comparing RVNA to conventional RVA pacing showed a non-statistically 
significant difference in left ventricular ejection fraction (LVEF) favoring RVNA pacing.7, 8 
Although there have since been a number of clinical studies comparing RVA to RVNA sites, 
overall results have been inconsistent and no clear pacing position superiority has emerged.   
There have been three meta-analyses comparing RVA to RVNA pacing that pooled 
data incrementally as trials accrued.9-11 The first meta-analysis by De Cock et al. pooled data 
from nine studies, and reported a significant difference in hemodynamic effect in favor of 
RVNA pacing .9 However, these results could not be extrapolated to long-term pacemaker 
implants as only two of the nine studies included in their analysis examined mid to long-term 
outcomes.  More recently, two meta-analyses10, 11  specifically considered study duration but 
the combined trials were markedly heterogeneous in terms of inclusion criteria.  The 
heterogeneity resulted in wide confidence intervals even with longer term follow-up 
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[Weighted mean difference (WMD) 4.27; 95% CI 1.15 – 7.40 and 3.58; 95%CI: 1.80 – 5.35].  
These intervals may still be too narrow given that the statistical model these studies utilized 
potentially underestimated the statistical error.12, 13 However, both meta-analyses concluded 
that RVNA pacing in general was better than RVA pacing in terms of protection of LV 
function and that a greater than 12 months follow-up was required to document the 
superiority of RVNA pacing.10, 11  No adverse outcome from RVNA was also noted.10  
Since the last meta-analysis there have been a number of further publications 
including a large randomized trial14 and a number of smaller trials.15-22 As a result we have 
undertaken this review to address the issues discussed above by providing further analyses 
that we feel deals specifically with the heterogeneity across studies. 
 
Methods 
Search strategy and selection criteria 
A systematic review and meta-analysis was conducted in accordance with the 
PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) 
guidelines.23 Four medical and life sciences databases (PubMed, Embase, Cochrane 
Central Register of Controlled Trials [CENTRAL] and Cochrane Database of Systematic 
Reviews) were searched from inception to October 2014 for randomized controlled trials that 
compared LVEF at baseline and after pacing lead placement in RVNA or RVA. The search 
strategy included the terms “Cardiac Pacing, Artificial”, or “Pacing(s)”, together with “Heart 
Ventricles” or “Ventricle(s)” or “Ventricular”, and “select-site pacing ” together with either 
“randomised study”, “randomised trial”, or “controlled clinical trial” and was modified to 
ensure the use of the correct database-specific syntax. The complete search strategy for 
PubMed is available in Appendix 1. In order to achieve a comprehensive evaluation of the 
published evidence, the systematic search was combined with the first 20 related citations of 
each included paper for qualifying publications that were not identified in the initial 
systematic search.24  
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 Inclusion was restricted to human studies, full-text articles, and randomized 
controlled trials comparing LVEF in RVA pacing with RVNA pacing irrespective of whether 
this was the primary endpoint. Non-apical leads were mostly, but not definitely, placed in the 
septum. We did not attempt to distinguish septal from non-septal locations because 
fluoroscopy, used widely to adjudicate final lead position, either alone or in conjunction with 
ECG criteria do not allow clinicians adequate discrimination between mid-septal, free wall 
and RVOT sites.25, 26 Data for LVEF measurements at baseline and at follow-up had to be 
available in an extractable format. Trials that included bi-ventricular pacing were excluded 
from the meta-analysis. Exclusions were also made for conference presentations and 
abstracts, or studies that presented data in a non-extractable format (i.e. graphical 
representation). There were no language restrictions on trial eligibility. Corresponding 
authors were contacted for further information regarding the mean LVEF and standard 
deviations if this was missing in the report.  
Study selection and data extraction 
Two authors (MH and LFK) independently confirmed the eligibility of studies and 
collated the data from the qualifying studies. MH extracted the data which were double 
checked by LFK and discrepancies were resolved through discussion and consensus 
following independent evaluation by another author (SARD). Data from the included studies 
were extracted and summarized in a spreadsheet. The recorded fields included study 
identifiers (authors, publication year, country); trial characteristics (design, randomization 
method, blinding, sample size, pacing parameters, location of RVNA pacing site, duration of 
follow-up); study population characteristics (age, gender proportion); and outcome (mode of 
LVEF assessment, LVEF baseline and post pacing placement). 
Quality assessment 
The quality of each study was assessed using expanded bias criteria as 
recommended in the Cochrane Handbook.27 The quality scale assessed 5 different types of 
bias (design, selection, information, confounding, and analytical bias) through 17 questions 
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as outlined in Appendix 2. A univariate quality score was also computed to rank each study 
by summing item scores and the maximum possible sum was 25 points. The study rank was 
determined as each study score divided by the maximum score in the list thus creating a 
quality rank that starts at 1 for the best study and has a minimum value of zero.   
Statistical analysis 
The primary endpoint was the percentage difference in LVEF at end of follow-up between 
RVNA and RVA pacing sites. In order to avoid between study heterogeneity, the studies 
were grouped into two homogenous sub-groups based on the effect magnitude and defined 
by visual and statistical homogeneity of the effects within each group. The subgroups were 
group one where the weighted mean difference (WMD) was in favor of RVNA pacing; and 
group 2 where WMD was not different between RVNA and RVA pacing. The weighted mean 
differences (WMD) in LVEF across studies were pooled using three different meta-analytic 
models, given that the random effects (RE) model28 is known, among other problems, to 
underestimate the statistical error and lead to overconfident results.12 The two other 
statistical approaches used were the bias adjusted quality effects (QE) model29  and its bias 
unadjusted variant called the inverse variance heterogeneity (IVhet) model30.  Both, the QE 
and the IVhet models use a quasi-likelihood based variance structure without distributional 
assumptions and thus have coverage probabilities for the CI well within the 95% nominal 
level and have been documented to have a better performance when compared to the RE 
method.31  Cochran's Q test and the
2I were used to assess heterogeneity amongst studies. 
2I >50% was considered to indicate practically significant heterogeneity.  
An inverse variance weighted generalized linear model was used to gain additional 
insight into differences between positive and negative studies by supplementing the meta-
analysis with investigation of important clinical differences between trials. The differences 
studied were defined a priori as 1) studies with a mean age of 70 years or more in both 
groups, 2) studies not solely recruiting AV node ablation/AV block indications for pacing, 3) 
studies which included subjects whose LVEF was poor (less than 40% 32) and 4) studies 
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whose duration of follow-up was at least 12 months. Such studies were coded 1 and the 
remainders under each criterion were coded 0.  Year of study publication was also 
considered as a variable but later dropped as it correlated with duration of follow-up. The 
generalized linear model was fit on the dichotomized outcome group (one versus two) of 
each study (coded 1 and 0 respectively) using a Poisson regression with a log-link and 
robust error variance in order to generate weighted rate ratios based on the study level 
predictors.33 This regression used the inverse of the variance of each study as weights to 
allow the observations with the least variance to provide the most information to the model. 
Finally, we ran a pre-post mean gain meta-analysis for each arm (RVNA and RVA) by 
subgroup. The mean gain and its standard error were computed as follows: 
2 1g T TES X X     
n
rs
SE
p
g
)1(2 2 
  
2/)( 22
2
1
2
TTp sss   
where T1 and T2 denote the baseline and end of follow-up respectively and 
2
ps  is the pooled 
variance across both time-points and r is fixed at 0.5.  Publication bias was assessed 
through visual inspection of Funnel and Doi plots.34  All tests were two-tailed and a p-value 
of less than 0.05 was deemed statistically significant. All the meta-analyses were conducted 
using MetaXL version 2.0 (EpiGear Int Pty Ltd; Brisbane, Australia; http://www.epigear.com). 
The generalized linear model was run in Stata version 12, StataCorp LP, College Station, 
TX, USA. 
Results 
Yield of search strategy 
The search strategy identified 662 unique publications, the titles and abstracts of 
which were screened for inclusion. The full text of 105 articles was retrieved, of which 21 
studies met the inclusion criteria plus three studies that were identified through related 
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citations. The 24 studies contributed 26 datasets (two studies contributed two datasets each) 
of which 14 datasets examined the effects of right ventricular pacing site on LVEF at one 
year or more and the remaining 12 datasets looked at shorter term effects. Reasons for 
exclusion of the remaining articles are indicated in Figure 1. 
Characteristics of the included studies 
The included studies recruited 1628 participants. The proportion of male subjects 
ranged from 20% to 100% in different studies. The mean or median age reported across 
studies ranged between 58 to 79 years. Thirteen studies included mainly caucasian 
populations7, 8, 14, 21, 22, 35-42, eight were conducted exclusively in Asian individuals15, 19, 20, 43-47 
and one each in Mexico16, Iran18 and Argentina.17 Inclusion citeria included chronic high 
degree AV Block, post AV node ablation,7, 8, 14-19, 21, 35-43, 45-47 symptomatic sick sinus 
syndrome18, 35, 38, 39, and chronic atrial tachyarrhythmia7 and bradyarrhythmias.22, 44, 45 Fifteen 
studies (seventeen datasets) documented LVEF as an inclusion criterion (Table 1).7, 14, 15, 17, 
19, 21, 35, 37, 41-47 Six studies (six datasets)  had an inclusion criterion specifically for patients 
with ejection fraction less than 40%.7, 19, 21, 37, 41, 42 The LVEF was reported at baseline in both 
groups in 19 studies (21 datasets),7, 14-17, 20-22, 35-40, 42, 43, 45-47 and omitted in five studies (five 
datasets).8, 18, 19, 41, 44 Of those who reported LVEF at baseline, the mean level was less than 
35% in two studies (2 datasets),7, 21 35–45% in one study (1 dataset) 42 and >45% in 18 
studies (18 datasets).7, 14-17, 20, 22, 35-40, 42, 43, 45-47 In four studies LVEF was measured with 
nuclear imaging7, 8, 42, 46 and in one using quantitative gated SPECT15. The rest were 
measured with standard trans-thoracic echocardiography. Most trials used a mid/lower or 
high right ventricular septum (RVS) site for RVNA pacing,8, 14-17, 19, 21, 22, 35-37, 42, 44, 45 , nine 7, 18, 
20, 38, 39, 41, 43, 46, 47 used the RVOT and in one study the RVNA lead was placed at the His 
bundle.40 Five studies incorporated crossover designs7, 8, 40-42 whereas the others were all 
parallel group studies15-22, 35-39, 43-47 (Table 1 and Appendix 4). 
The quality score ranged (Appendix 3) from 10 to 23 out of 25 possible points. Three 
studies were double-blinded,14, 16, 22 and eight studies were single blind.8, 18, 21, 35, 38, 40, 41, 47. In 
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12 studies blinding was not described.7, 15, 17, 19, 20, 36, 37, 39, 42-46 A rigorous method of 
randomization was explicitly described in only one study,14 and in four studies, though 
randomization was described, concealment was unclear;19, 37, 45, 46 . In the remainder, this 
information was absent or unclear. Three studies43, 44, 47 did not provide details of participants 
who withdrew or were lost to follow-up. Participant completion rates ranged from 69 to 100% 
for RVA group and 70 to 100% in RVNA group.  Length of follow-up was at least 2 months in 
those followed up for less than 12 months and at most 120 months in those who had more 
than 12 months follow up. Out of 24 studies included in meta-analysis only one study 
followed intention-to-treat analysis14 (Appendix 3). 
Quantitative synthesis 
There were two homogenous subgroups created based on visual inspection of the 
forest plot and statistical assessment of heterogeneity (Table 2).  In terms of LVEF 
difference at the end of follow-up, fourteen datasets were in group 2 where no difference 
between RVNA and RVA pacing was evident (bias adjusted WMD -0.07; 95% CI: -1.14 to 
1.01) and 12 datasets were in the group 1 where a benefit for RVNA compared to RVA 
pacing was seen (bias adjusted WMD 5.40; 95% CI: 3.94 to 6.87). Group 2 had studies that 
all individually reported a mean difference in LVEF at the end of follow-up of less than 2%. 
The results using the other statistical models concurred (Table 2). The Chen et al study had 
the largest weight because the standard deviations reported were the smallest among the 
group of studies and not consistent with study size.19 When this study was excluded from the 
analysis, results remained similar (Table 2).    
The mean gain in LVEF was negligible across arms in group 2 (Figure 2, bottom 
panel) while in group 1, there was a net loss in systolic function over time for the RVA arm 
but not for the RVNA arm (Figure 2, top panel).  When we looked at study level predictors of 
group 1 membership, there was an interaction between inclusion of poor LVEF and longer 
duration of follow-up, such that the trials with this combination were more common within 
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group one (weighted RR 2.82; Table 3). Older age also was more common within group one 
(weighted RR 3.49; Table 3).  
On visual inspection of the Doi and funnel plots (all studies), there was symmetry 
(intercept -0.49, P=0.446) when assessed using Egger’s regression. Both plots (Figure 3) 
looked visually symmetrical. 
Discussion 
Accumulating evidence has suggested that RVA pacing may adversely affect LV function 
and results from the DAVID trial focused clinical attention on the adverse clinical effects of  
RV pacing.48  This trial demonstrated that RV pacing increased the risk of heart failure and 
death in a group of patients with poor baseline LV function compared with a cohort in whom 
ventricular pacing was minimized. Other studies have subsequently also shown a lower risk 
of heart failure hospitalization where baseline LV function was preserved and where there 
were associated co-morbidities such as pre-existing ventricular conduction delay, previous 
myocardial infarction or heart failure.49, 50 One of these, the MOST study, reported a <2% 
hospitalization for heart failure linked to pacing over 2 years where baseline LV function prior 
to pacing was normal and in the absence of pre-existing cardiac pathology.51 Where there 
was pre-existing pathology, there was a marked increase in the risk of heart failure 
hospitalization, by up to 50%.48, 49 The largest randomized trial to date, the Protect-Pace 
study published recently, recruited only subjects with exclusively good baseline LV function 
and did not find a difference in LVEF between RV apical and high septal pacing sites after 
two years of follow up.14 This outcome was also noted in the Danpace sub-study where RV 
lead position did not appear to influence the rate of heart failure in patients without significant 
co-morbidity and with good baseline LVEF.50  
 Our meta-analysis agrees with these results and confirms that an important factor 
linked to pacing-induced LV dysfunction is indeed impaired LV function prior to pacing.52 We 
have pooled previous and new studies using a rigorous statistical approach in order to 
address differing enrolment criteria and different study durations. This approach uses 
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subgroups where study effects were homogenous to identify possible effects of poor LVEF. 
We then used a weighted regression approach to elucidate the impact of poor LVEF and 
related factors and our results provide compelling evidence supporting the superiority of 
RVNA pacing over RVA pacing in terms of left ventricular systolic function preservation.  
In summary, protection was seen predominantly where studies belonged to group 
one (three times more likely to includes studies with subjects who had poor baseline LVEF), 
and we report a weighted mean LVEF at end of follow-up to be between 4-7% higher in the 
RVNA as opposed to RVA arms while no significant difference was seen in group two. 
Additional analysis suggests that where studies belonged to group one (three times more 
likely to includes studies with subjects who had poor baseline LVEF), a deterioration also 
occurs over time (pre-post follow-up) with RVA pacing, which was not seen in group 2. The 
outcome of our analysis therefore suggests that where baseline LV function is preserved, 
studies report the same effect of chronic RVA and RVNA pacing in terms of LVEF changes 
over time. However, where baseline LV function is impaired (inclusion of LVEF<40%) 
studies are more likely to report a significant reduction in LVEF with RVA compared to RVNA 
pacing. This was especially so when study follow-up was in excess of twelve months though 
a trend for lesser follow-up could not be excluded. Another factor that seems to play a role 
that we could identify was the inclusion of more elderly subjects.   
Our study confirms the results of the two previous meta-analyses and emphasizes 
the importance of baseline LV function at the time of pacemaker implant in relation to lead 
placement.  Traditionally right ventricular pacing has been the mainstay of delivery of anti-
bradycardia support, the technology proving stable and highly reliable. Clinical studies have 
emphasized the need to minimize right ventricular pacing suggesting that perhaps RV 
pacing itself, irrespective of site, may be deleterious.53 As a result of concerns over chronic 
RVA pacing, other sites, in particular the RV septum or outflow-tract have been extensively 
studied. Despite compelling experimental data supporting a septal pacing site,6 individual 
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clinical studies have provided inconsistent results when comparing the latter to the apical 
pacing site and the reasons for this are now becoming clearer. 
Other modalities which can be used in lieu of RVNA/RVA pacing include cardiac 
resynchronization therapy (CRT), His bundle pacing, and dual site right ventricular pacing. 
Guidelines recommend CRT where there is LBBB and impaired LV function and so will also 
be applicable where there is RV pacing induced LBBB type morphology. Of three clinical 
studies comparing CRT to RV pacing, two showed a favorable outcome for CRT54, 55 
whereas one was inconclusive.56 In the Block-HF study, the QRS width was not particularly 
broad at study inclusion. However widespread use of CRT will be constrained by cost, 
expertise and the small but consistent problems with reliable LV lead placement which in 
some studies has been as high as 10 percent.57 In pacing dependency, LV lead failure then 
reverts the patient to RV pacing. His bundle pacing is also attractive as it utilizes the HPS for 
ventricular depolarization. Although there has been a recent upsurge in interest there remain 
technical issues which may prevent widespread dissemination, particularly high pacing 
thresholds and the difficulties with reliable His bundle capture. However, newer approaches 
have provided more reliable outcomes and future large scale studies will determine whether 
His bundle has a more widespread future In small scale studies dual site RV pacing has also 
shown promise but there are no large scale data and further trials are required.58, 59 
In summary, the body of experimental evidence evaluated through this meta-analysis 
strongly suggests that RVA pacing causes deleterious effects on LV systolic function in 
selected patients, and that non-apical pacing prevents this from occurring.  In our analysis, 
group one appears to benefit most from RVNA pacing. This group has a greater probability 
of containing those with impaired baseline LV function, more elderly subjects and those with 
longer (greater than a year’s) follow-up, supporting an ongoing deleterious effect from pacing 
in those patients with already impaired LV function. Where baseline LV function is preserved 
it does not appear that either RVA or RVNA pacing produces a significant and clinically 
important difference in LV function accepting that the longest follow-up period was two 
  
This article is protected by copyright. All rights reserved.   13 
 
years. From this meta-analysis, we therefore cannot exclude the possibility that RVNA 
pacing results in a more gradual deterioration in LVEF when baseline LV function is 
preserved rather than no deterioration at all. However, 1-2 years is sufficient to discern 
differences in LV function, suggesting that the impact is related to the already compromised 
nature of the ventricle. A clinical trial into the effect of RVA versus RVNA pacing in patients 
with impaired LV function would be ethically difficult to justify. A study comparing RVNA to 
cardiac resynchronization therapy (CRT) might be more acceptable and provide a clear 
answer but will be difficult to perform clinically due to the observed beneficial outcomes of 
studies with CRT in patients with heart block.55, 60 However from observational studies, most 
patients do not have a deleterious outcome to RV pacing and perhaps, as implanters, we 
need to be better at identifying those patients where LV function is likely to deteriorate with 
RV pacing. This meta-analysis therefore provides support for a change in clinical approach: 
we suggest that where LV function is preserved then pacing either at the RVA or RVNA is 
acceptable. Where LV function is significantly impaired (LVEF <35%) a RVNA position 
together with optimal medical treatment is also valid, although CRT may be a better initial 
pacing mode. Where CRT is unavailable or not achievable then RVNA should be the site of 
choice. If baseline LV function is mild to moderately impaired (LVEF 35-50%) there is 
support for a RVNA lead and regular monitoring of LVEF will identify those patients where 
LV function continues to deteriorate.  
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Tables 
Table 1.- Left ventricular ejection fraction characteristics of studies included in the meta-
analysis 
Auth
or, 
year 
of 
publi
catio
n 
LV
EF 
as 
an 
inc
lus
ion 
crit
eri
a 
Method  
of 
LVEF 
assess
ment 
Baseline 
LVEF (% 
±SD) 
Final 
LVEF (% 
±SD) 
Mean 
percenta
ge of 
ventricul
ar pacing 
at the 
end of 
the 
follow up 
(RVA / 
RVNA) 
 
Outcome/ Remarks 
RV
A 
RVN
A 
RV
A 
RV
NA 
Qua
lity 
Sco
res 
(out 
of 
25) 
Can
o et 
al, 
2010 
Ye
s; 
≥5
0% 
Echocar
diograp
hy 
62.
9±6
.3 
64.2
±8.0 
62.9
±7.9 
66.5
±7.2 
RVA= 
88%  and 
RVNA= 
81% 
20 No differences in 
LVEF, NT-pro BNP, 
6-minute walk, NYHA 
functional class 
Che
n et 
al, 
2014 
Ye
s; 
35 
to 
40
% 
Echocar
diograp
hy 
NSD 36.7
±0.7 
41.8
±2.2 
RVA=94
% AND 
RVNA=93
% 
14 RVNA provides a 
better clinical utility, 
compared with RVA, 
in patients with high-
degree AV block and 
moderately 
depressed LV 
function whose LVEF 
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levels ranged from 
35% to 40%. 
Dom
enic
hini 
et al, 
2012 
No Echocar
diograp
hy 
54.
0±8
.0 
52.0
±13.
0 
55.0
±8.0 
 
46.0
±15.
0 
99% in all 
patients 
20 No differences in 
LVEF between 
groups 
Flev
ari et 
al, 
2009 
No Echocar
diograp
hy 
47.
0 
±13
.2$
 
52.0 
±13.
2$
 
43.0 
± 
12.0
$ 
59.0 
± 
12.0
$ 
RVA= 
97% and 
RVNA=95
% 
17 Increase in LVEF 
with septal pacing  
Gon
g et 
al, 
2009 
Ye
s; 
>5
0% 
Echocar
diograp
hy 
67.
9 
±6.
4 
68.3 
±6.4 
65.7 
±6.6 
67.6 
± 
5.2 
RVA=  
97% and 
RVNA=98
% 
16 RVNA had no benefit 
over RVA pacing in 
aspect of preventing 
cardiac remodelling 
and preserving LV 
systolic function after 
12 months of pacing 
in patients with 
normal cardiac 
function 
Hem
ayat 
et al, 
2014 
No Echocar
diograp
hy 
NSD 58.1
±6.1 
59.3
±3.8 
RVA=55.
61% and 
RVNA=62
.49% 
12 LVEF did not vary 
significantly between 
RVA and RVNA 
pacing 
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Inou
e et 
al, 
2011 
Ye
s; 
≥4
0% 
Echocar
diograp
hy 
NSD 65.0
±6.0 
68.0
±6.0 
RVA=92.
7% and 
RVNA=94
.3% 
10  
 
No added advantage 
with RVNA on LVEF 
Kaye 
et al, 
2014 
Ye
s; 
≥4
0% 
Echocar
diograp
hy 
57.
0 
±9.
0 
56.0
±10.
0 
55.0
± 
9.0 
54.0 
± 
10.0 
RVA= 
98% and 
RVNA= 
93% 
23 RVNA  pacing does 
not provide a 
protective effect on 
left ventricular 
function over RVA 
pacing in the first 2 
years 
Krist
ians
en et 
al, 
2012 
Ye
s; 
≤3
5% 
Echocar
diograp
hy 
25.
0 
±4.
0 
24.0 
±4.0 
31.0 
± 
6.0 
31.0 
± 
8.0 
Not 
reported 
20 No improvement in 
LVEF 
Kypt
a et 
al, 
2008 
Ye
s; 
≤4
0% 
Echocar
diograp
hy 
59.
0±1
1.0 
55.0
±11.
0 
57.0
±10.
0 
57.0 
± 
10.0 
RVA= 
95% and 
RVNA= 
91% 
18 No differences in 
LVEF, NT-proBNP or 
exercise 
Lang
e et 
al. 
2014 
Ye
s; 
≥4
5% 
Echocar
diograp
hy 
58±
7.1 
57.8
±9.3 
62.3
3±7.
8 
59.2
8±8 
98% in all 
patients 
16 LVEF did not vary 
significantly between 
RVA and RVNA 
pacing 
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Leon
g et 
al, 
2010 
No Echocar
diograp
hy 
60.
0±6
.0 
61.0
±9.0 
52.0 
± 
9.0 
60.0 
± 
7.0 
RVA=95
% and 
RVNA=97
% 
21 Better LVEF and 
remodelling with 
RVNA septal pacing 
Lewi
cka-
Now
ak et 
al, 
2006 
No Echocar
diograp
hy 
56.
0±1
1.0 
54.0
±7.0 
47.0 
± 
8.0 
53.0 
± 
9.0 
RVA=99
% and 
RVNA= 
94% 
15 Better LVEF and 
diastolic function with 
RVNA 
Mera 
et al, 
1999 
No Nuclear 
Imaging 
Not 
mentioned 
43.0
±10.
0 
51.0
±14.
0 
Permane
nt 
ventricula
r capture 
since 
patient 
underwen
t AV node 
ablation 
15 RVS pacing 
produces shorter 
QRS duration and 
better chronic LV 
function than RVA 
pacing in patients 
with mild to moderate 
LV dysfunction and 
chronic AF after His 
bundle ablation. 
Resting LVEF better 
with RVNA. 
Moli
na et 
al, 
No Echocar
diograp
hy 
52.
0±1
0.0*
 
57.0
±10.
0* 
54.0 
(11.
0)a
 
61.0 
(7.0
)a 
98% 
ventricula
r pacing 
were 
14 Patients with septal 
ventricular leads 
have better clinical 
and functional 
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2014 included (LVEF)  outcome 
Occ
hetta 
et al, 
2006 
No Echocar
diograp
hy 
51.
9±8
.8 
51.9
±8.8 
50.0
±7.9 
53.4
±7.9 
Consisten
t 
ventricula
r capture 
as 
patients 
undergon
e AV 
node 
ablation 
20 Compared with 
conventional right 
apical pacing, it 
allows an 
improvement in 
functional and 
hemodynamic 
parameters over 
long-term follow-up. 
Sta
mble
r et 
al, 
2003 
Ye
s; 
≤4
0% 
Echocar
diograp
hy 
NSD 41.0  
± 
13.4 
43.8  
± 
14.4 
>90% in 
both RVA 
and 
RVNA 
groups 
15 No differences in 
LVEF, NYHA, 6-
minute walk 
Tse 
et al, 
2002 
Ye
s; 
≥5
0% 
Nuclear 
Imaging 
57.
0±1
2.0 
59.0 
± 
14.0 
47.0  
± 
10.3
$ 
56.0  
± 
3.4$
 
RVA=95
% and 
RVNA=97
% 
18 Better LVEF and 
diastolic function with 
RVNA 
Tse 
et al, 
2009 
Ye
s; 
>5
0% 
Echocar
diograp
hy 
58.
0± 
4.0 
59.0 
± 
5.0 
59.6 
± 
6.5$
 
59.5 
± 
8.31
$ 
Permane
nt 
ventricula
r capture 
as 
19 In patients with 
permanent AF, 
RVNA, but not at 
RVA, preserves 
LVEF and provides 
  
This article is protected by copyright. All rights reserved.   27 
 
patients 
undergon
e AV 
node 
ablation 
incremental benefit 
for exercise capacity 
Vict
or et 
al, 
1999 
Ye
s; 
<4
0% 
Nuclear 
Imaging 
51.
0 ± 
9.0 
49.0 
± 
6.0 
48.0
±10.
0 
45.0 
± 
9.0 
Permane
nt 
ventricula
r capture 
as 
patients 
undergon
e AV 
node 
ablation 
19 No differences in 
LVEF, VO2 max and 
CO 
Vict
or et 
al, 
1999 
Ye
s; 
≥4
0% 
Nuclear 
Imaging 
27.
0±9
.0 
27.0 
± 
9.0 
30.0
±10.
0 
28.0 
± 
9.0 
Permane
nt 
ventricula
r capture 
as 
patients 
undergon
e AV 
node 
ablation 
19 No differences in 
LVEF, VO2 max and 
CO 
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Vict
or et 
al, 
2006 
Ye
s; 
≥4
5% 
Nuclear 
Imaging 
52.
0±6
.0 
52.0 
± 
6.0 
51.0 
± 
7.0 
52.0 
± 
6.0 
Permane
nt 
ventricula
r capture 
as 
patients 
undergon
e AV 
node 
ablation 
19 Better LVEF with 
septal pacing in 
patients with ECG 
baseline LVEF < 
45% 
Vict
or et 
al, 
2006 
Ye
s; 
<4
5% 
Nuclear 
Imaging 
38.
0± 
5.0 
38.0
± 
5.0 
37.0 
±4.0 
42.0 
± 
5.0 
Permane
nt 
ventricula
r capture 
as 
patients 
undergon
e AV 
node 
ablation 
19 
Wan
g et 
al, 
2011 
Ye
s; 
≥5
5% 
Echocar
diograp
hy 
63.
7±6
.5 
65.2
±4.5 
63.2 
± 
5.0 
63.4 
± 
4.3 
>95% in 
both 
groups 
18 The RVNA pacing in 
AV block patients 
over 1 year may be 
superior to RVA 
pacing in terms of 
regional LV 
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performance, LV 
global 
electromechanical 
delay, and IVMD, 
although 
intraventricular 
dyssynchrony and LV 
volumes do not differ. 
Zhan
g et 
al, 
2012 
No Echocar
diograp
hy 
59.
5±6
.21 
57.8
2±6.
06 
54.2
±8.7 
56.9 
± 
5.54 
RVA=82.
91% and 
RVNA=82
.79% 
19 LVEF did not 
markedly vary in the 
RVNA group 
compared to RVA,  
compared to RVA 
pacing, RVNA 
(RVOTS) pacing had 
no remarkable 
benefit in terms of 
preventing cardiac 
remodelling 
Zhan
g et 
al, 
2014 
Ye
s; 
≥4
5% 
Echocar
diograp
hy 
(Baselin
e 
measur
64.
0 
±07
.0 
63.0 
±04.
0 
59.0
±13.
0 
59.0
±11.
0 
>95% in 
all 
patients 
17 There were no 
significant changes in 
LVEF, LV end-
systolic volume, and 
LV end-diastolic 
volume from 
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ement); 
Quantit
ative 
Gated 
SPECT(
end line 
measur
ement) 
the 1-week follow-up 
to the 6-month 
follow-up in the 
RVNA and RVA 
groups. 
*Measured at 1st week after implantation; a Median (IQR); $- standard deviation was 
estimated from reported Standard error; RVA-Right Ventricular Apical; RVNA-Right 
Ventricular Non-Apical; NSD- Non significant difference; NYHA-New York Heart Association; 
NT Pro BNP- N-terminal prohormone of brain natriuretic peptide. 
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Table 2. Meta-analysis results 
Subgroup Statistical model 
%LVEF difference* 
(95% CI) 
Cochran's 
Q 
P 
(Cochran’s 
Q) 
Number 
of study 
datasets 
Group 1 Bias adjusted (QE) 5.40 (3.94 – 6.87) 16.40 0.23 12 
 IVhet  4.97 (3.31 – 6.62)    
 Random effects  5.13 (3.80 – 6.47)    
Group 1  Bias adjusted (QE) 5.30 (3.51 – 7.09) 16.27 0.18 11 
Excluding IVhet  4.79 (2.93 – 6.66)    
Chen et al Random effects  5.34 (3.58 – 7.11)    
Group 2 Bias adjusted (QE)  -0.07 (-1.14 – 1.01) 14.23 0.36 14 
 IVhet   0.42 (-0.61 – 1.44)    
 Random effects   0.30 (-0.71 – 1.31)    
* Weighted mean difference (RVNA – RVA) 
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Table 3: Rate ratios for group 1 membership according to study selection criteria* (Poisson 
regression using a log-link and binomial outcome with robust error variance and study 
inverse variance weighted) 
 
Selection criterion Rate ratio P [95% Conf. Interval] 
Other indications 2.04 0.173 (0.73, 5.66) 
Older subjects 3.49 0.055 (0.98, 12.45) 
Long duration (good LVEF) 1.08 0.906 (0.32. 3.64) 
Interaction     
Poor LVEF     
      of long duration 2.82 0.043 (1.03, 7.72) 
      of short duration 3.16 0.120 (0.74, 13.48) 
*Results were in a similar direction after exclusion of Chen et al .19 
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Figures 
 
Figure 1: PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-
Analyses) flowchart of the literature search conducted in August 2014 for the 
systematic review and meta-analysis. 
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Figure 2: Mean gain in LVEF from baseline to end of follow-up in group 1(top panel) 
and group 2(bottom panel). (a) RVNA arms of included studies; (b) RVA arm of 
included studies. Studies not reporting LVEF at baseline were excluded. 
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Figure 3: Funnel (a) and Doi (b) plots of all studies 
 
 
